Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. orthocat

ORTHOCAT SIGNED

Bioorthogonal Photocatalytic Activation of Metal-Based Prodrugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ORTHOCAT project word cloud

Explore the words cloud of the ORTHOCAT project. It provides you a very rough idea of what is the project "ORTHOCAT" about.

clinics    4619    strategy    orthocat    inside    generate    vectors    anticancer    dual    photosensitizer    solid    proposes    class    reducing    patient    unconventional    prodrug    tumour    hypoxic    innovative    effectiveness    nevertheless    therapeutic    activating    prodrugs    combines    dna    death    wellbeing    metal    photocatalyst    oxygen    nanoplatforms    act    light    cellular    imbalance    catalytic    cell    once    simultaneously    framework    potentially    2017    mitochondrial    mechanism    efficiency    multidisciplinary    singlet    sci    tumours    cancer    photodynamic    care    involve    mission    transition    organelle    new    selectively    redox    selectivity    kill    background    vast    designing    original    mitochondria    photochemistry    successful    limits    species    fewer    therapy    photoactivatable    riboflavin    action    synergistically    pdt    photochemotherapy    chem    cells    employing    delicate    depends    drugs    intimately    photocatalytic    pt    compounds    convenient    efficacy    accumulate    triphenylphosphonium    surgery    agents    accomplishes    outcome    complexes    homeostasis    trigger    activation    strategies   

Project "ORTHOCAT" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER 

Organization address
address: PASEO MANUEL LARDIZABAL 4
city: DONOSTIA SAN SEBASTIAN
postcode: 20018
website: http://dipc.ehu.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-10   to  2020-09-09

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER ES (DONOSTIA SAN SEBASTIAN) coordinator 158˙121.00

Map

 Project objective

New cancer care methodologies with fewer side effects and no need for major surgery are required to enhance patient wellbeing. Photodynamic Therapy (PDT) partially accomplishes such mission employing light and a photosensitizer. Nevertheless, the PDT mechanism of action intimately depends on oxygen, which limits its efficacy, particularly in hypoxic solid tumours. Promising strategies to improve the impact of PDT in the clinics currently involve the design of photoactivatable transition metal complexes, a class of compounds which combines the rich photochemistry of metal complexes with the vast background of metal-based drugs in cancer therapy.

In this framework, ORTHOCAT proposes an original and multidisciplinary strategy to exploit the efficiency and selectivity of riboflavin as unconventional photocatalyst for the activation of Pt(IV) anticancer prodrugs (Chem. Sci. 2017, 8, 4619).

The project aims at designing novel riboflavin-based catalytic systems capable of activating Pt(IV) anticancer prodrugs inside the mitochondria of tumour cells. In particular, I will use triphenylphosphonium targeting vectors to develop new photocatalytic prodrug systems and delivery nanoplatforms which selectively accumulate in the mitochondria. Once in the organelle, riboflavin will act as singlet oxygen photosensitizer for PDT and simultaneously as photocatalyst to generate Pt(II) species for targeting mitochondrial DNA (photochemotherapy). Imbalance of mitochondrial delicate redox homeostasis by ORTHOCAT dual agents can trigger cell death through convenient cellular pathways. Therefore, ORTHOCAT prodrug systems will synergistically kill cancer cells with increased effectiveness, while potentially reducing side effects of metal-based drugs. Successful outcome of the project has the potential to deliver innovative therapeutic agents for cancer photochemotherapy.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-08-05 15:14:49

Take a look to the deliverables list in detail:  detailed list of ORTHOCAT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORTHOCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORTHOCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

BRCAstem (2020)

Monitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells

Read More  

Laminar-PL (2019)

Ultra-high field imaging of perceptual learning and human brain plasticity

Read More  

THE CROSSMODAL BRAIN (2020)

Neural mechanisms of crossmodal activity in blind and sighted individuals

Read More